Franklin Resources Inc. Raises Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Franklin Resources Inc. boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.3% during the third quarter, Holdings Channel.com reports. The firm owned 16,405 shares of the company’s stock after buying an additional 1,538 shares during the period. Franklin Resources Inc.’s holdings in Intellia Therapeutics were worth $320,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. State Street Corp grew its holdings in shares of Intellia Therapeutics by 17.9% in the third quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after purchasing an additional 780,754 shares during the last quarter. Patient Square Capital LP bought a new stake in Intellia Therapeutics in the 3rd quarter worth $2,642,000. Dimensional Fund Advisors LP increased its position in shares of Intellia Therapeutics by 8.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company’s stock valued at $29,648,000 after acquiring an additional 98,865 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Intellia Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock valued at $17,006,000 after acquiring an additional 37,714 shares during the last quarter. Finally, Verition Fund Management LLC raised its stake in shares of Intellia Therapeutics by 116.3% during the third quarter. Verition Fund Management LLC now owns 94,426 shares of the company’s stock valued at $1,940,000 after acquiring an additional 50,763 shares during the last quarter. Institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $11.66 on Thursday. The company has a 50 day simple moving average of $14.23 and a two-hundred day simple moving average of $19.58. Intellia Therapeutics, Inc. has a fifty-two week low of $11.34 and a fifty-two week high of $34.87. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.14 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. During the same period last year, the business earned ($1.38) EPS. The firm’s quarterly revenue was down 24.1% on a year-over-year basis. On average, analysts forecast that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on NTLA shares. Chardan Capital boosted their price target on Intellia Therapeutics from $88.00 to $91.00 and gave the company a “buy” rating in a report on Monday, November 18th. Oppenheimer reduced their target price on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating on the stock in a research note on Monday, November 11th. StockNews.com raised Intellia Therapeutics to a “sell” rating in a research note on Friday, November 8th. Canaccord Genuity Group reissued a “buy” rating and set a $90.00 price objective on shares of Intellia Therapeutics in a research report on Tuesday, November 19th. Finally, Citigroup dropped their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Intellia Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.94.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.